For the first time in history, the people with the capital, the lived experience, and the investment sophistication are the same people. Here is what that convergence means for private capital.
Thank you Kathleen and it's a convergence that's only going to become harder to ignore as the wealth transfer accelerates. The next piece in this series goes deeper into what it actually means for capital allocation.
Great question Alex. The short answer is: indirectly but meaningfully.
Public markets exposure to women's health is still thin. Most of the pure-play companies are private. But the convergence I describe creates conditions that will eventually surface in public markets. As the category validates through private capital, the exit routes lead either to public listings or to acquisition by publicly traded strategics like Bayer, Organon, AstraZeneca, or Novo Nordisk etc. So the public markets investor who wants to position ahead of this is largely doing it today through the large pharma and medtech names that are actively building women's health pipelines. The pure-play public opportunity is still forming.
The more interesting public markets signal right now is actually on the demand side; frameworks at publicly listed wealth management firms. More on this in a future piece.
Great post! I hadn’t considered the convergence - thank you!
Thank you Kathleen and it's a convergence that's only going to become harder to ignore as the wealth transfer accelerates. The next piece in this series goes deeper into what it actually means for capital allocation.
Do you have an opinion on how this might affect public investment?
Great question Alex. The short answer is: indirectly but meaningfully.
Public markets exposure to women's health is still thin. Most of the pure-play companies are private. But the convergence I describe creates conditions that will eventually surface in public markets. As the category validates through private capital, the exit routes lead either to public listings or to acquisition by publicly traded strategics like Bayer, Organon, AstraZeneca, or Novo Nordisk etc. So the public markets investor who wants to position ahead of this is largely doing it today through the large pharma and medtech names that are actively building women's health pipelines. The pure-play public opportunity is still forming.
The more interesting public markets signal right now is actually on the demand side; frameworks at publicly listed wealth management firms. More on this in a future piece.